Safety and efficacy of apatinib in combination treatment versus apatinib as second-line treatment for advanced gastric cancer.

Front Oncol · 2025 · PMC12074971 · PMID 40371231

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.1960

boldest claim

The sentences

highly significantP<0.001actually significant

The magnitude of survival benefit and highly significant P-values (both P<0.001) results indicated that the superiority of combination therapy in prolonging both PFS and OS for advanced gastric cancer patients undergoing second-line treatment.

also in 132,142 other papers

did not reach statistical significanceP = 0.196not close (p > 0.1)

The overall response rates (ORR) were 14.0% (6/43, 95 %CI: 6.6%-27.3%) and 24.5% (13/53, 95 %CI: 14.9%-37.6%), respectively, which did not reach statistical significance (χ2=1.67, P = 0.196).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.